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treatment and treatment location; quality of life depends on
symptom severity (measured by the PANSS score) and side-
effects. Multivariate sensitivity analyses were carried out to
assess the robustness of results. RESULTS: An indirect compari-
son of trial data suggests that paliperidone ER (6 mg) and olan-
zapine (10 mg) are equally efﬁcacious in terms of PANSS
reduction, while the former has a superior side-effect proﬁle,
especially with respect to weight gain and sedation. In the model
this reduction in side effects on paliperidone ER translates into
(discounted) QALY gains of ~0.03 compared to olanzapine.
These health beneﬁts are realized at (discounted) incremental
costs ranging from -€3200 (-23,800 DKK) in Denmark to cost-
neutrality in Finland, suggesting either dominance or cost-
effectiveness in all four countries. The sensitivity analysis
suggests results are robust to changes in input parameters. If the
side-effect proﬁle of paliperidone ER is assumed to improve
compliance, further cost-savings and QALY gains are predicted.
CONCLUSION: Based on the available evidence and input from
local experts, paliperidone ER is predicted to dominate olanza-
pine in Sweden, Norway, Finland and Denmark. Results are
robust to changes in input parameters. Improved compliance on
paliperidone ER due to reduced side effects would further
strengthen its predicted dominance.
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OBJECTIVES: To estimate cost-effectiveness of various therapy
scenarios of treating schizophrenia with amisulprid (Solian), a
medicine of 2nd generation, in comparison with haloperidol.
METHODS: Cost-effectiveness decision model was prepared.
Treatment with amisulprid vs haloperidol was compared in fol-
lowing scenarios: Ø Scenario 1—amisulprid vs haloperidol
(with change for risperidon in case of recurrence in any arm) Ø
Scenario 2—amisulprid vs. haloperidol for 1 year (as ﬁrst line
medicine) followed by treatment with new atypical medicine
(olanzapina or risperidon) in case of recurrence. The target
population was patients suffered from chronic schizophrenia, at
the moment of exacerbation of disease. Analysis was performed
from the payers’ perspective (the National Health Budget and
patient), with a time horizon of 1 year. Estimates of effective-
ness were expressed with QALY (quality adjusted life years).
Following parameters were considered: risk of extrapyramidal
symptoms, recurrence, suicide and rates of compliance. Costs
of medicines (ﬁrst line therapy with amisulprid or haloperidol
and possibly second line therapy with olanzapina or risperidon
in case of recurrence in haloperidol arm), correcting therapy
with olanzapine or rispridone in case of recurrenece), treatment
of EPS, hospitalisation due to reccurence and outpatient con-
sultations were taken into account. RESULTS: In the scenario 1
cost of 1 QALY due to replacing standard ﬁrst line therapy
with haloperidol by amisulprid is 1601 PLN. In scenario 2,
using amisulprid during one year instead of haloperidol as ﬁrst
line therapy followed by olanzapina in case of recurrance,
brings additional costs of 275 PLN and gives additional QALY
0.056 year. Cost of quality adjusted life year is 4935 PLN.
CONCLUSION: Treatment of schizophrenia with amisulprid
during whole year, instead of haloperidol as ﬁrst line therapy
followed by risperidon in case of recurrence, is a cost effective
therapy.
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OBJECTIVES: This study determines the cost-effectiveness of 3
antipsychotics for the treatment of schizophrenia in Belgium.
METHODS: Data were retrieved from a prospective observa-
tional non randomized follow-up survey. Clinical investigators
included 293 schizophrenic patients; 136 of those patients were
assigned to Olanzapine, 129 to Risperidone and 28 to Haloperi-
dol. Patients were followed for 2 years. Total health care costs
were determined from the perspective of the public payer and
calculated by multiplying resource use with ofﬁcial tariffs; effec-
tiveness of the drugs was measured with EQ-5D. Several studies
have already compared the cost-effectiveness of different antip-
sychiotics for the treatment of schizophrenia, most of them are
however ﬂawed by methodological issues. This study therefore
uses a new method that was developed to address these limita-
tions but is not widely used yet: the net-beneﬁt regression
approach (NBRA). We show its merits by performing a cost-
effectiveness analysis of Olanzapine, Risperidone and Haloperi-
dol. RESULTS: Models were checked for selection bias but drug
choice was not endogenous; we therefore proceeded with simple
OLS regressions. The results indicate that the drugs provide
similar net monetary beneﬁts to the patient (H vs. O -4452.53
(p = 0.645), R vs. O 4439.54 (p = 0.425), R vs. H 8892.07
(p = 0.366)). When we control for several patient characteristics
R moves away further from H and O but the difference does not
reach statistical signiﬁcance (R vs. O 5857.73 (p = 0.332), R vs.
H 15233.53 (p = 0.178)). Several important patient subgroups
were also identiﬁed; they indicate that a drug performs better in
a speciﬁc patient group. Numerous sensitivity analyses conﬁrm
the robustness of the results. CONCLUSION: We conclude by
conﬁrming that the NBRA is an important enrichment to the
CEA methodology. As was demonstrated in this paper, it is often
important to correct cost-effectiveness results for patient charac-
teristics and to identify signiﬁcant patient subgroups.
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OBJECTIVES: Major depressive disorder (MDD) remains highly
under-treated and accounts for substantial health system costs.
Duloxetine, a new serotonin and norepinephrine reuptake inhibi-
tor, has been shown to be effective and safe in treatment of
depression. This study examined the cost-effectiveness of dulox-
etine vs. Selective Serotonin Reuptake Inhibitors (SSRIs: ﬂuoxet-
ine, paroxetine, sertraline, citralopram and escitalopram) and
venlafaxine extended-release (XR) from the Spanish health
system perspective. METHODS: A Markov decision model
simulated clinical management of MDD patients during six
2-month cycles in primary or secondary care. Patients on acute
treatment could experience remission, response without remis-
sion, no response, or discontinuation of initial therapy. Non–
responders and partial responders could continue therapy or
switch to another therapy. Efﬁcacy data and utility data were
derived from clinical trials. Treatment patterns were obtained
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from interviews with practising Spanish GPs and psychiatrists.
Costs from ofﬁcial price/tariff lists were applied. Model out-
comes included total treatment cost, quality-adjusted life years
(QALYs) and symptom-free days (SFD). The robustness of ﬁnd-
ings was assessed in sensitivity analyses. RESULTS: In primary
care, incremental cost per QALY for duloxetine vs Venalaxine
XR was €29,457 and for duloxetine vs SSRIs was between
€11,867–€21,957 (extreme values vs paroxetine and ﬂuoxetine,
respectively). Incremental cost per SFD was 13€ vs. Venlafaxine
XR and ranged from 14€ to 26€ vs. paroxetine and ﬂuoxetine
respectively. In secondary care duloxetine was dominant vs. all
the drugs except for the comparison with ﬂuoxetine (cost per
QALY gained was 650€ and cost per additional SFD was 1€).
Results were sensitive to changes in the trial remission and
response rates, and in the distribution of switch therapy options.
CONCLUSION: Duloxetine showed a reasonable cost-
effectiveness ratio vs. the comparator drugs and could therefore
be considered a cost-effective treatment for MDD patients in
primary and secondary care in Spain.
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OBJECTIVES: To assess the cost-effectiveness of escitalopram
versus generic paroxetine in the treatment of generalized anxiety
disorder (GAD) in Norway. METHODS: Cost-effectiveness
analysis was based on a decision-tree model, reﬂecting the
current guidance for the treatment of GAD. Escitalopram
10–20 mg/day was compared to paroxetine 20–50 mg/day, the
only SSRIs licensed for the treatment of GAD in Norway. Initial
treatment started in primary care; failure to respond to a second-
line SSRI after switch from initial treatment resulted in referral to
a psychiatrist. The evaluation was performed over a 9-month
time horizon. Model data sources included published clinical
trials and standard national data sources. The main effectiveness
outcome was ﬁrst-line treatment success, deﬁned as a response
after 12 weeks of treatment (50% reduction in HAM-A) and
absence of relapse during the following 24 weeks. Other out-
comes included quality-adjusted life years (QALYs), rate of main-
tained treatment response (response at week 12 maintained at
week 36) and rate of referrals to secondary care. The analysis
was performed from the societal perspective and evaluated direct
treatment costs, including out-of-pocket payments and costs
covered by health insurance. RESULTS: Patients treated with
escitalopram had 11.3% higher ﬁrst-line success and 5.4%
higher maintained response rates compared with paroxetine-
treated patients. Rates of referrals to secondary care were 5.5%
lower with escitalopram compared with paroxetine. Per patient
direct treatment costs associated with escitalopram and paroxet-
ine treatment amounted to NOK 4424 and NOK 4172, respec-
tively. Incremental cost-effectiveness ratio (ICER) was NOK
2,230 per ﬁrst-line treatment response and NOK 37,612 per
QALY. Sensitivity analyses demonstrated robustness of the model
to changes in key input parameters. CONCLUSION: Escitalo-
pram appears to be cost-effective compared with paroxetine in
the treatment of GAD in Norway, based on direct treatment
costs.
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OBJECTIVES: The oral variant of the antipsychotic drug risperi-
done will lose patent protection at the end of 2007, which opens
the market for generic variants. However, since many schizo-
phrenic patients suffer from paranoia, some of them will be less
willing to take a different drug. Switching might therefore cause
non-compliance, which is in its turn the most important predic-
tor of relapse and hospitalisation in schizophrenia. We therefore
made an estimation of potential economic consequences regard-
ing drug and hospitalisation costs when stable patients in The
Netherlands currently using branded risperidone are switched to
the generic version. METHODS: A simple health economic
model was developed, based on published data regarding hospi-
talisation durations, rates of compliance, relapse, and additional
relapse resulting from switching to generics. A one-year perspec-
tive was applied. RESULTS: Due to a somewhat higher relapse
rate after switching to generics in the ﬁrst year after the switch,
total per-patient drug and hospitalisation costs were estimated to
be higher for the generic product as compared to the branded
product (€5110 and €4680, respectively). Sensitivity analyses
showed the stability of the relative result. CONCLUSION:
Switching patients who are stabilised on branded risperidone to
the generic version might cause higher health care costs. The
analysis is dependent on assumptions, but given their evidence-
based character, there is sufﬁcient reason to believe that the
relative result will hold in countries where only a little difference
will exist between the price of branded and generic risperidone
after the patent expiry.
PMH30
DIRECT COSTS ASSOCIATED WITH MILD COGNITIVE
IMPAIRMENT IN PRIMARY CARE
Luppa M1, Heinrich S1, Matschinger H1, Hensel A1, Luck T1,
Kaduszkiewicz H2, Riedel-Heller SG1, Koenig HH1
1University of Leipzig, Leipzig, Saxony, Germany, 2University of
Hamburg, Hamburg, Hamburg, Germany
OBJECTIVES: Little is known about the direct costs of individu-
als with mild cognitive impairment (MCI). This study investi-
gates the direct costs associated with MCI according to recent
diagnostic criteria from a societal perspective. METHODS: A
total of 452 primary care patients aged 75+ from Leipzig,
Germany, were investigated in face-to-face interviews regarding
MCI according to the current diagnostic criteria of the Interna-
tional Working Group on MCI, resource utilisation and costs
(cost diary), as well as chronic medical illness (Chronic Disease
Score). Resource utilisation was monetarily valued using 2004/
2005 prices. RESULTS: Mean annual direct costs were EUR
4443 for patients with MCI (N = 39) and EUR 3,814 for patients
without MCI (N = 413) (p = 0.34). Looking at the cost compo-
nents, patients with and without MCI only signiﬁcantly differed
regarding pharmaceutical costs (EUR 1210 vs. EUR 1062;
p < 0.05) not caused by antidementive drugs. CONCLUSION:
Direct costs of individuals having MCI are not signiﬁcantly
increased in comparison to direct costs of individuals without
cognitive deﬁcits.
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